NASH Mouse Experiment Found Drug-Specific Midazolam Pharmacokinetic Changes

Liver disease and gut microbial effects did not change every probe medicine in the same way.

What the publication shows

The mouse study compared a drug cocktail after intragastric and intravenous administration and used host-enzyme and microbial experiments. Midazolam exposure was higher in the NASH model than in controls in the reported oral comparison. The investigators found differing contributions of host metabolism and gut microbiota across the probe drugs.

Limits of the evidence

This was a disease-model animal experiment, not a dosing study in patients with human NASH. Mouse enzyme systems, experimental diets and cocktail administration limit direct extrapolation. An oral apparent-clearance difference incorporates bioavailability as well as elimination.

Application to expert review

For pharmacokinetic reasoning, retain route, parent and metabolite results and the particular disease model. Do not infer one universal liver-disease multiplier for every benzodiazepine. Human concentration interpretation requires case-specific clinical and analytical evidence.

Source and related reading

Source: Publication PMC9263650. The case-review applications above are interpretive analysis.